225 related articles for article (PubMed ID: 35443168)
1. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
[TBL] [Abstract][Full Text] [Related]
2. The fusion oncogene VAV1-MYO1F triggers aberrant T-cell receptor signaling in vivo and drives peripheral T-cell lymphoma in mice.
Morrish E; Wartewig T; Kratzert A; Rosenbaum M; Steiger K; Ruland J
Eur J Immunol; 2023 Mar; 53(3):e2250147. PubMed ID: 36541400
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.
Abate F; da Silva-Almeida AC; Zairis S; Robles-Valero J; Couronne L; Khiabanian H; Quinn SA; Kim MY; Laginestra MA; Kim C; Fiore D; Bhagat G; Piris MA; Campo E; Lossos IS; Bernard OA; Inghirami G; Pileri S; Bustelo XR; Rabadan R; Ferrando AA; Palomero T
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):764-769. PubMed ID: 28062691
[TBL] [Abstract][Full Text] [Related]
4. VAV1 mutations contribute to development of T-cell neoplasms in mice.
Fukumoto K; Sakata-Yanagimoto M; Fujisawa M; Sakamoto T; Miyoshi H; Suehara Y; Nguyen TB; Suma S; Yanagimoto S; Shiraishi Y; Chiba K; Bouska A; Kataoka K; Ogawa S; Iqbal J; Ohshima K; Chiba S
Blood; 2020 Dec; 136(26):3018-3032. PubMed ID: 32992343
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.
Robles-Valero J; Fernández-Nevado L; Lorenzo-Martín LF; Cuadrado M; Fernández-Pisonero I; Rodríguez-Fdez S; Astorga-Simón EN; Abad A; Caloto R; Bustelo XR
EMBO J; 2021 Nov; 40(22):e108125. PubMed ID: 34617326
[TBL] [Abstract][Full Text] [Related]
6. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.
Boddicker RL; Razidlo GL; Dasari S; Zeng Y; Hu G; Knudson RA; Greipp PT; Davila JI; Johnson SH; Porcher JC; Smadbeck JB; Eckloff BW; Billadeau DD; Kurtin PJ; McNiven MA; Link BK; Ansell SM; Cerhan JR; Asmann YW; Vasmatzis G; Feldman AL
Blood; 2016 Sep; 128(9):1234-45. PubMed ID: 27297792
[TBL] [Abstract][Full Text] [Related]
7. Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.
Drieux F; Ruminy P; Sater V; Marchand V; Fataccioli V; Lanic MD; Viennot M; Viailly PJ; Sako N; Robe C; Dupuy A; Vallois D; Veresezan L; Poullot E; Picquenot JM; Bossard C; Parrens M; Lemonnier F; Jardin F; de Leval L; Gaulard P
J Mol Diagn; 2021 Aug; 23(8):929-940. PubMed ID: 34147695
[TBL] [Abstract][Full Text] [Related]
8. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
Wang T; Feldman AL; Wada DA; Lu Y; Polk A; Briski R; Ristow K; Habermann TM; Thomas D; Ziesmer SC; Wellik LE; Lanigan TM; Witzig TE; Pittelkow MR; Bailey NG; Hristov AC; Lim MS; Ansell SM; Wilcox RA
Blood; 2014 May; 123(19):3007-15. PubMed ID: 24497534
[TBL] [Abstract][Full Text] [Related]
9. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
[TBL] [Abstract][Full Text] [Related]
10. [Genetic alterations in new category of Peripheral T-cell lymphoma, not otherwise specified].
Fukumoto K
Rinsho Ketsueki; 2022; 63(12):1657-1667. PubMed ID: 36653140
[TBL] [Abstract][Full Text] [Related]
11. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.
Huang YH; Qiu YR; Zhang QL; Cai MC; Yu H; Zhang JM; Jiang L; Ji MM; Xu PP; Wang L; Cheng S; Zhao WL
Cell Rep Med; 2024 Feb; 5(2):101416. PubMed ID: 38350451
[TBL] [Abstract][Full Text] [Related]
12. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Heavican TB; Bouska A; Yu J; Lone W; Amador C; Gong Q; Zhang W; Li Y; Dave BJ; Nairismägi ML; Greiner TC; Vose J; Weisenburger DD; Lachel C; Wang C; Fu K; Stevens JM; Lim ST; Ong CK; Gascoyne RD; Missiaglia E; Lemonnier F; Haioun C; Hartmann S; Pedersen MB; Laginestra MA; Wilcox RA; Teh BT; Yoshida N; Ohshima K; Seto M; Rosenwald A; Ott G; Campo E; Rimsza LM; Jaffe ES; Braziel RM; d'Amore F; Inghirami G; Bertoni F; de Leval L; Gaulard P; Staudt LM; McKeithan TW; Pileri S; Chan WC; Iqbal J
Blood; 2019 Apr; 133(15):1664-1676. PubMed ID: 30782609
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.
Ludvigsen M; Bjerregård Pedersen M; Lystlund Lauridsen K; Svenstrup Poulsen T; Hamilton-Dutoit SJ; Besenbacher S; Bendix K; Møller MB; Nørgaard P; d'Amore F; Honoré B
Blood Adv; 2018 Oct; 2(19):2533-2542. PubMed ID: 30291111
[TBL] [Abstract][Full Text] [Related]
15. Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.
Sakata-Yanagimoto M; Fukumoto K; Karube K; Chiba S
J Clin Exp Hematop; 2021 Jun; 61(2):61-70. PubMed ID: 33716242
[TBL] [Abstract][Full Text] [Related]
16. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Iqbal J; Wright G; Wang C; Rosenwald A; Gascoyne RD; Weisenburger DD; Greiner TC; Smith L; Guo S; Wilcox RA; Teh BT; Lim ST; Tan SY; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Tubbs RR; Ott G; Geissinger E; Gaulard P; Piccaluga PP; Pileri SA; Au WY; Nakamura S; Seto M; Berger F; de Leval L; Connors JM; Armitage J; Vose J; Chan WC; Staudt LM;
Blood; 2014 May; 123(19):2915-23. PubMed ID: 24632715
[TBL] [Abstract][Full Text] [Related]
17. Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.
Debackere K; Marcelis L; Demeyer S; Vanden Bempt M; Mentens N; Gielen O; Jacobs K; Broux M; Verhoef G; Michaux L; Graux C; Wlodarska I; Gaulard P; de Leval L; Tousseyn T; Cools J; Dierickx D
Nat Commun; 2021 Jun; 12(1):3705. PubMed ID: 34140493
[TBL] [Abstract][Full Text] [Related]
18. A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
Kuczynski EA; Morlino G; Peter A; Coenen-Stass AML; Moss JI; Wali N; Delpuech O; Reddy A; Solanki A; Sinclair C; Calado DP; Carnevalli LS
EMBO Mol Med; 2022 Jun; 14(6):e15816. PubMed ID: 35510955
[TBL] [Abstract][Full Text] [Related]
19. GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma.
Zhang W; Wang Z; Luo Y; Zhong D; Luo Y; Zhou D
Oncotarget; 2016 Oct; 7(40):65284-65294. PubMed ID: 27589565
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
